ArticleAnnals of translational medicine2022

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.

Chenxia Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.